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Abstract
The transformation of a normal cell into a cancer cell takes place through a sequence of a small number of
discrete genetic events, somatic mutations: thus, cancer can be regarded properly as a genetic disease of somatic
cells. The analogy between evolution of organisms and evolution of cell populations is compelling: in both cases
what drives change is mutation, but it is Darwinian selection that enables clones that have a growth advantage to
expand, thus providing a larger target size for the next mutation to hit. The search for molecular lesions in tumors
has taken on a new dimension thanks to two powerful technologies: the micro-arrays for quantitative analysis of
global gene expresssion (the transcriptome); and ‘deep’ sequencing for the global analysis of the entire genome (or
at least the exome). The former offers the most complete phenotypic characterization of a tumor we could ever
hope for – we could call this the ultimate phenotype; the latter can identify all the somatic mutations in an
individual tumor – we could call this the somatic genotype. However, there is definitely the risk that while we are
‘drowned by data, we remain thirsty for knowledge’. If we want to heed the teachings of Lorenzo Tomatis, I think
the message is clear: we ought to take advantage of the new powerful technologies – not by becoming their
slaves, but remaining their masters. Identifying somatic mutations in a tumor is important not because it qualifies
for ‘oncogenomics’, but because through a deeper understanding of the nature of that particular tumor it can help
us to optimize therapy or to design new therapeutic approaches.
Introduction
Lorenzo Tomatis was a towering figure in the study of
cancer and cancer epidemiology: not just because from
1982 to 1993 he was the Director of the International
Agency for Research against Cancer (IARC), but even
more because he commanded immense international
respect as a scientist ahead of his time in the under-
standing of the environmental causes of cancer. Toma-
tis’ major influence in this area spanned some four
decades [1,2] (see Figs. 1a and 1b). I never worked with
Renzo, but I have vivid memories of many encounters
and discussions I had with him, both about science and
about research policies: and I am forever grateful for
what I learnt from him.
My job today is to discuss the role of somatic muta-
tions in oncogenesis. In a nutshell, and using a time-
honoured terminology of medicine, if heredity and
environment are the aetiology of cancer, somatic
mutations are the essence of its pathogenesis. With
respect to heredity, it is abundantly clear that one never
does inherit cancer, but rather one may inherit an
increased risk of cancer [3]. In first approximation,
some mutant genes entail a very high risk of cancer, so
much so that they behave as Mendelian dominants (see
Fig. 2), and they are therefore called high penetrance
(cancer susceptibility) genes. These include (i) tumor
suppressors (e.g. p53, APC, GPC3, VHL, CDKN2A,
MEN1), (ii) oncogenes (e.g. PDGFRA, KIT, MET, RET),
and (iii) genes required for genome stability (e.g. ATM,
BLM, FANCA, BRCA2, MSH2, XPA). Known high pene-
trance genes number by now several dozens [4]: they
may have tumor (site) specificity (e.g. BRCA2)o rt h e y
may not (e.g. p53). In addition, numerous clinical obser-
vations (see for instance Fig. 3 [5]) indicate that cancer
susceptibility may ‘run in families’ in a more subtle way,
and this has led to the notion of low penetrance (cancer
susceptibility) genes [6]. These are important because
they may contribute significantly to the cancer burden
in a population (see Figure 4). Until recently, candidate
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on first degree relatives [7], (ii) kinship analysis [8], (iii)
studies on twins [9], and (iv) linkage disequilibrium ana-
l y s i si na p p r o p r i a t ep o p u l a t i o n s[ 1 0 - 1 2 ]I tm u s tb e
admitted that until recently the yield has been limited,
although individual examples have turned up, for
instance among genes involved in signal transduction
pathways (e.g. the TGFb receptor: see Fig. 5), and
numerous genes involved in DNA repair (Figure 6). Over
the past 4 years, however, genome-wide association stu-
dies (GWAS) have become very popular: this is not a
conceptually new approach, as it is merely an updated
version of (iv), but it is made much more powerful
through the availability of some millions single nucleo-
tide polymorphisms (SNPs). Thanks to this increased
power, many low penetrance genes or loci have been
Figure 1 Headings of one of the first and on of the last publications by Lorenzo Tomatis.
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evidence of carcinogenicity in the primary 
prevention of cancer 
 
Lorenzo Tomatis 
International Society of Doctors for the Environment (ISDE), Trieste, Italy 
Figure 2 Pedigree of a family with a high rate of breast cancer and ovarian cancer: the increased tendency to developing cancer shows a
Mendelian autosomal dominant pattern of inheritance, suggesting that a single gene is largely responsible.
MENDELIAN INHERITANCE OF CANCER 
Figure 3 In this extended family there were 3 cases of hairy cell leukaemia (HCL): their co-existence can be hardly a coincidence,
since HCL is one of the rarest forms of B cell leukaemia. Here the pattern is not Mendelian, suggesting that several genes and/or
environmental factors are involved.
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TWO TYPES OF CANCER GENES 
Figure 5 Meta-analysis of the quantitative effect of a polymorphic allele of the TGF b receptor gene on the frequency of some types of tumors.
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ARE INVOLVED IN DNA REPAIR 
Gene  N studies  Type of tumor(s)  Notes 
BRCA2  2 Breast  R,  M 
CCND1  2  Head & Neck  R, M 
ERCC1  2 Bladder  D,  M 
ERCC2  53 Bladder;  lung  R,  D,  M 
ERCC4  6 Breast  R,  M 
ERCC5  2 Lung  R,  M 
MGMT  2 Prostate  R,  D,  M 
NBN  4 Bladder  D,  M 
PARP1  2 Breast  R,  S 
POLI  3 Lung  D,  M 
TP53  115  Breast; cervix; lung  R, D, M, S 
XPA  8 Lung  R,  NC 
XRCC1  21  Cervix; esophageal; head & neck; skin; stomach  R, D, M, NC 
XRCC2  2 Colorectal  D,  M 
XRCC3  37 Breast;  stomach  R,  D,  M,  NC 
XRCC4  2 Bladder  D,  S 
(From Vineis et al:, JNCI 101: 24-36, 2009) 
Figure 7 A cartoon illustrating current views of the origin of cancer, which is consequent on n successive somatic mutations. The final
result is a clonal population of cells with highly disregulated growth. It can be presumed that in fact each one of the mutational steps entails a
growth advantage, even if small: this increases the number of cells that can be targeted by the next mutation. The term n-1 is used to indicate
the penultimate step in the pathway, because the number n is not fixed: it is estimated that it may range, for the majority of tumors, from 3 to
6 or even more.
Kaklamani, V. G. et al. J Clin Oncol; 21:3236-3243 2003 
Figure 6 A genetic polymorphism in the coding sequence of the TGF-b receptor gene influences the risk of cancer.
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Figure 8
POPULATION GENETICS IS APPLICABLE TO POPULATION OF CELLS  
Events/processes  In populations of organisms  In populations  
of somatic cells 
Mutation  Creates a mutant 
individual/family 
Creates a mutant cell/clone 
Lethal mutation  No offspring  No clonal growth 
Neutral mutation  No visible change  No visible change 
Mutation with absolute 
advantage 
Mutant people will gradually 
take over 
Clone will grow faster than 
other cells 
Mutation with conditional 
advantage 
Mutant people will increase 
in a certain environment 
Clone will grow faster under 
certain conditions 
Figure 9 Inherited mutations can increase cancer proneness through different mechanisms. The top section of the cartoon is a schematic
of the process outlined in Fig. 5. The middle section illustrates how an increased rate of somatic mutations can produce an accelerated rate of
the oncogenic pathway: this is the case for instance for patients with Fanconi anemia, who have a serious defect in DNA repair and often
develop cancer at a young age. The bottom section illustrate that the number of steps for a normal cell to become a cancer cell is cut by one if
the first mutation is an inherited (germ-line) mutation rather than an acquired somatic mutation: this is the case for instance for patients who
have an APC mutation and present with familial adenomatous polyposis.
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Page 6 of 11now identified, that affect the risk of individual types (or
several types) of cancer – mostly by less than +/- 30% –
in one or another population (see 40 references in
webappendix of recent paper by Hartman et al. [13] .
With respect to the environment, I think the most last-
ing monumental memorial to Lorenzo is the series of
IARC publications on carcinogenic agents which, in the
jargon of the cognoscentes,a r ek n o w ns i m p l ya sThe
Monographs. Rarely has an international agency been able
to generate publications (each one the product of a colle-
gial effort) with so much scientific content; even more
rarely has this taken place consistently in dozens of
volumes over some thirty years, to the extent that the
Monographs are universally regarded as the ultimate
authority on their individual topics; and probably never
has a single person – namely Tomatis himself – through
his scientific rigor, his incredible dedication, and his
unique ability to catalyze consensus whenever possible,
contributed so much to a successful venture of this nature.
The model of oncogenesis pioneered by John Cairns
[14] contained already the key for reconciling aetiology
and pathogenesis. The transformation of a normal cell
into a cancer cell takes place through a sequence of a
small number of discrete genetic events, somatic muta-
tions (Figure 7): thus, cancer can be regarded properly
as a genetic disease of somatic cells [3,15]. The analogy
between evolution of organisms and evolution of cell
populations is compelling (Figure 8): in both cases what
drives change is mutation, but it is Darwinian selection
that enables clones that have a growth advantage to
expand, thus providing a larger target size for the next
mutation to hit [14,16,17] (Figure 7). This model offers
a simple interpretation to the mechanism of action of
the aetiological factors we have mentioned. An environ-
mental agent can increase the rate of somatic mutation
(i.e., it may be mutagenic, like ionizing radiation), or it
can increase the rate of cell proliferation (as when Heli-
cobacter pylori causes gastritis), or it may do both things
(this is probably the case with the hepatitis B virus caus-
ing hepatoma). As for heredity, in the majority of cases
it acts probably by increasing the mutation rate, and
this may apply to both high penetrance genes and to
low penetrance genes; on the other hand, sometimes an
oncogene with a germ-line mutation appears to be in
lieu of the first somatic mutation, for instance in the
case of RET in Multiple Endocrine Neoplasia type 2,
thus decreasing by one the number of mutations
required for the development of cancer (see Figure 9).
In order to understand the pathogenesis of tumors we
must consider their very extensive variety: not only can
Subject with average cancer susceptibility 
Subject with increased 
cancer risk: 
Increased rate 
of somatic mutations 
Subject with  
increased cancer risk: 
First cancer  
mutation  
In germ-line 
TWO MECHANISMS OF INHERITED INCREASED SUCEPTIBILITY TO DEVELOPING 
CANCER 
Figure 10 A graphic representation (current referred to as a cyclo-plot) of the multiple defects detected in the genome of a tumor (a
small-cell lung cancer cell line) by deep sequencing. Individual chromosomes are depicted on the outer circle followed by concentric tracks
for point mutation, copy number and rearrangement data relative to mapping position in the genome. Arrows indicate examples of the various
types of somatic mutation present in this cancer genome. From Stratton et al., 2009 (ref. 29).
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body, but even within the set of tumors arising from a
specific type of cell there is marked heterogeneity, some
of it well explored and some yet to be unravelled. The
somatic mutation-Darwinian selection model of cancer
is appropriately versatile: we can presume, and we know
in specific cases that different genes are involved: some
400 have been already identified [18]. To this end, the
methodology that has given the highest returns has been
cytogenetic analysis, which has spotted (i) chromosomal
translocations harbouring fusion genes or rearrange-
ments that dysregulate gene expression, as well as (ii)
loss of heterozigosity betraying deletions. In other cases
somatic mutations have been discovered in genes
already known to have germ-line mutations in cancer-
prone families, or by deliberately testing for somatic
mutations in candidate genes. Not surprisingly, many of
the genes involved belong to sets that are relevant to
broad functions within the cell (the buzz-term today is
gene ontology): particularly the cell cycle, signalling, reg-
ulation of transcription, apoptosis and, once again, gen-
ome stability (DNA repair) [19,20].
The search for molecular lesions in tumors has taken
on a new dimension thanks to two powerful technolo-
gies: the micro-arrays for quantitative analysis of global
gene expression [21-25] (the transcriptome); and ‘deep’
sequencing for the global analysis of the entire genome
(or at least the exome). The former offers the most com-
plete phenotypic characterization of a tumor we could
ever hope for – we could call this the ultimate pheno-
type; the latter can identify all the somatic mutations in
an individual tumor – we could call this the somatic
genotype (see Figure 10). The ground-breaking paper
[26] on the latter was published in 2006; and already it
has been followed by a flurry of similar work on differ-
ent types of tumors [27-30]. The somatic genotype of
MR Stratton et al. Nature 458, 719-724 (2009) doi:10.1038/nature07943 
Figurative depiction of the landscape of  
somatic mutations present in a single cancer genome.
Figure 11 Figurative depiction of the landscape of somatic mutations present in a single cancer genome.
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Page 8 of 11the tumor can be fully characterized by sequencing in
parallel (from non-tumor DNA) also the inherited gen-
ome of the patient: thus, the issue of inherited variation
versus acquired somatic mutation can be rigorously cir-
cumvented. A more difficult issue has to do with the
fact that somatic mutations can occur (indeed are rela-
tively common) in any normal cell: therefore a somatic
mutation found in a tumor does non automatically qua-
lify as being causative of that tumor; therefore we must
improve algorithms aiming to disentangle driver muta-
tions (i.e. pathogenic mutations) from passenger muta-
tions. At any rate, by this approach not only are new
genes being identified; also, patterns of mutations are
emerging (Figure 11) that may be signatures of exposure
to individual environmental mutagens [26]: an unex-
pected bonus of molecular studies that is highly relevant
to the focus of this meeting.
Somatic mutations are central to the process of onco-
genesis, because almost certainly no tumor can arise
without them (although epigenetic phenomena are
important [31-33], I think it is highly unlikely that gene
silencing by promoter methylation alone can do the
job). The rate of somatic mutations – and thus the risk
of cancer – can be increased by inherited genes or by
environmental agents, as we have outlined; however,
somatic mutations occur all the time as spontaneous
stochastic events, because the replication of DNA is
extremely faithful but nor perfect: this means that there
is always an element of chance in oncogenesis (Figure
12). In this respect, we know surprisingly little about the
normal baseline somatic mutation rate (μ). Over the
past several years, by using the X-linked gene PIG-A as
a sentinel gene, we have developed a relatively simple
methodology to measure μ in any individual [34-36]: we
have determined the normal range of μ,a n dw eh a v e
shown that it is higher in severak groups of cancer-
prone subjects. It will be important to determine
whether μ correlates with the risk of sporadic cancer,
and whether we can measure changes in μ in subjects
who are exposed to environmental carcinogens. It is
also not unconceivable that μ could be decresed by
pharmacological agents.
The progress of contemporary biology has led us
within thirty years from a multitude of theories about
oncogenesis to the established fact that cancer is a
genetic disorder of somatic cells. On the other hand,
much recent literature gives the impression that there is
a surplus of information, from gene expression profiles
COLON BREAST  TOTAL 
Substitutions at CG base 
pairs 
CG to TA  413 (59.3)  289 (34.5)  702 (45.8) 
CG to GC  48 (6.9)  239 (28.5) 287  (18.7) 
CG to AT  93 (13.4)  148 (17.7)  241 (15.7) 
Substitutions at TA base 
pairs 
TA to CG  56 (8.0)  72 (8.6)  128 (8.3) 
TA to GC  51 (7.3)  35 (4.2)  86 (5.6) 
TA to AT  35 (5.0)  55 (6.6)  90 (5.9) 
Substitutions at specific 
dinucleotides 
5’-CpG-3’ 309  (44.4) 139  (16.6) 448  (29.2) 
5’-TpC-3’  79 (11.4)  257 (30.7)  336 (21.9) 
TOTAL 696  838  1534 
SOME SPECIFIC TYPES OF SOMATIC MUTATIONS  
FOUND IN TUMORS 
Figure 12 A cartoon illustrating the central role of chance in cancer formation, based on the fact that somatic mutations are stochastic
events. Inherited factors (see text and Fig. 6) can modulate the process, but they somatic mutations are still needed for the onset of cancer; and
environmental factors work in large measure by increasing either the mutation rate (mutagenic agents) or the number of cell divisions (e.g. with
an inflammatory process, such as one caused for instance by Helicobacter pylori).
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Page 9 of 11to proteomics to metabolomics, with the risk that while
we are truly ‘drowned by data, we remain thirsty for
knowledge’. If we want to heed the teachings of Lorenzo
Tomatis, I think the message is clear: we ought to take
advantage of the new powerful technologies – not by
becoming their slaves, but remaining their masters.
Identifying somatic mutations in a tumor is important
not because it qualifies for ‘oncogenomics’, but because
through a deeper understanding of the nature of that
particular tumor it can help us to optimize therapy or
to design new therapeutic approaches. Figure 13.
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